pH-mediated molecular differentiation for fluorimetric quantification of chemotherapeutic drugs in human plasma

05 December 2017, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

At present, drug dosage is based on standardised approaches that disregard pharmakokinetic differences between patients and lead to non-optimal efficacy and unnecessary side effects. In this work, we demonstrate the potential of pH-mediated fluorescence spectroscopy for therapeutic drug monitoring in complex media. We apply this principle to the simultaneous quantification of the chemotherapeutic prodrug Irinotecan and its active metabolite SN-38 from human plasma across the clinically relevant concentration range, i.e. from micromolar to nanomolar at molar ratios of up to 30:1.

Keywords

Irinotecan
fluorimetric quantification
point-of-care diagnostics
therapeutic drug monitoring
fluorimetry
Chemistry

Supplementary materials

Title
Description
Actions
Title
Serrano et al QIRSN38 ESI ChemRxiv v1
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.